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Genomic translocation events frequently underlie cancer development through generation of gene fusions with
oncogenic properties. Identification of such fusion transcripts by transcriptome sequencing might help to discover
new potential therapeutic targets. We developed TRUP (Tumor-specimen suited RNA-seq Unified Pipeline)
(https://github.com/ruping/TRUP), a computational approach that combines split-read and read-pair analysis
with de novo assembly for the identification of chimeric transcripts in cancer specimens. We apply TRUP to
RNA-seq data of different tumor types, and find it to be more sensitive than alternative tools in detecting
chimeric transcripts, such as secondary rearrangements in EML4-ALK-positive lung tumors, or recurrent inactivating
rearrangements affecting RASSF8.Background
Genomic rearrangements in cancer often lead to gene
fusions disrupting the activity of tumor suppressor genes
or activating proto-oncogenes, thus playing an important
role in tumor development. Gene fusions can lead to the
constitutive activation of a kinase, on which cancer cells
become dependent, a process sometimes referred to as
‘oncogene addiction’ [1]. One of the big successes in the
treatment of cancer was the identification of small mol-
ecules that specifically target fusion proteins, such as ima-
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article, unless otherwise stated.[2] or crizotinib in the case of EML4-ALK positive lung
tumors [3].
Paired-end transcriptome sequencing (PE RNA-seq) is
a powerful tool for the identification of fusion transcripts
in tumors [4]. However, the complexity of the cancer
transcriptome, the high dynamic range of gene expres-
sion, and the prevalence of sequencing errors confound
the computational fusion detection from RNA-seq data
[5]. Existing methods in this field primarily rely on read-
pair analysis by assuming that deviations of the mapping
distance or orientation are caused by fusion events [6,7].
To increase sensitivity, a split-read mapping method
may be adopted in addition to read-pair analysis [8,9].
However, the short reads typically generate a large num-
ber of candidates including many false positives that
need sophisticated further processing, which is computa-
tionally expensive. It has recently been shown that de
novo assembly of novel junctions in a targeted regioned Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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predictions, since it provides high quality and longer
sequences spanning the fusion point by leveraging de-
pendency among short reads [10].
In this study we present TRUP, a computational pipe-
line that combines split-read and read-pair analysis with
de novo assembly of candidate regions containing a poten-
tial breakpoint, to achieve sensitive and accurate detection
of fusion transcripts. TRUP afforded detecting secondary
in-frame rearrangements in EML4-ALK-positive lung
adenocarcinomas, as well as the identification of recurrent
inactivating rearrangements affecting the candidate tumor
suppressor gene RASSF8.
Results and discussion
TRUP: A pipeline for detecting fusion genes in cancer
In order to detect fusion transcripts from PE RNA-seq
data, we need to identify the fusion point from the se-
quencing read alignments. Discordant mapping of mate
pairs, which include chimeric as well as partial alignments
of an individual read, are reported by GSNAP [11] or
STAR [12]. To guarantee high sensitivity, TRUP collects
all candidate regions containing potential breakpoints
suggested by those abnormal alignments. Additionally,
for each candidate region, de novo assembly is per-
formed using de Bruijn graphs (‘Velvet’) [13] and a
modified version of Velvet (Oases) that employs add-
itional filters to afford optimized merging of multiple
assemblies, specifically of transcriptome sequencingFigure 1 Overview of the TRUP pipeline. The schematic diagram on the
cartoon on the right panel illustrates an example of detecting a fusion eve
and to gene B, respectively. In a first step, TRUP aligns the read pairs onto
and p7 in the cartoon) and partial alignments (p1, p3, p6, and p8). To guar
breakpoint, relaxed criteria are adopted to call breakpoints from chimeric/p
(p4 and p5). Subsequently, to reach high accuracy, de novo assembly is per
region. Lastly, bona fide breakpoints relative to the genome are identified f
a sufficient number of supporting reads. While the mapping and assembly
and fusion calling steps are novel (Materials and methods).data [14], with the aim to construct possible contigs
from each region by leveraging dependency among
reads. After sensitive split-read mapping and specific
de novo assembly, fusion candidates are filtered and
ranked based on repeat content and number of reads
supporting the fusion points (Figure 1; Materials and
Methods).
In order to evaluate the performance TRUP, we ini-
tially applied a preliminary version of TRUP (v1.0) to the
well-characterized lung cancer cell-lines H3122 and
H2228, which are known to harbor different variants of
the EML4-ALK fusion gene [15], as well as to five lung
adenocarcinoma tumor specimens that had been found
positive for ALK rearrangements by FISH. On average,
50 million PE reads were uniquely mapped to the human
genome (Additional file 1). We considered as high confi-
dence candidates those chimeric transcripts that matched
the following requirements: inter- or intra-chromosomal
rearrangements; at least five independent reads supporting
the breakpoint (either reads that span or read-pairs that
encompass the fusion-point, referred as spanning reads
and encompassing reads, respectively); and a non-
repetitive sequence across the fusion-point (unless the
chimeric transcript was also covered by encompassing
reads). We found that below 5x most of the candidates
called were artifacts of the pipeline or barely expressed
chimeric transcripts difficult to validate by RT-PCR. In the
seven samples analyzed, 20 chimeric transcripts matched
the above-mentioned requirements. Out of these 20, 17left panel shows the four major processing steps applied in TRUP. The
nt. White and black colored boxes indicate reads mapped to gene A
the genome allowing discovery of chimeric alignments (read pair id p2
antee a sensitive detection of candidate regions containing potential
artial alignments, as well as from entirely aligned discordant pairs
formed on a candidate region by using the read pairs anchored in this
rom the assembled sequences. A fusion candidate is called if it attracts
steps adopt the state-of-the-art algorithms, the breakpoint searching
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cing across the fusion-point, or by FISH in the case of
EML4-ALK (Table 1). These results were used to build
an improved version of TRUP (v2.0), which not only
recovered all the above-mentioned validated candi-
dates but also identified 28 additional high-confident
ones (Additional file 2). For all subsequent analyses
version 2.0 was used.
In order to determine the robustness and accuracy of
TRUP we applied our pipeline to a published PE RNA-
seq dataset of small cell lung cancer [16]. We applied
TRUP to the cell-line data, where experimental validation
of candidates was possible. We were able to identify
two novel fusion transcripts affecting histone modi-
fiers: one predicted to inactivate the histone acetyl-
transferase CREBBP in the cell line, N417, and the
other one leading to the inactivation of the TAF6-
like RNA polymerase II p300/CBP-associated factor
(PCAF)-associated factor (TAF6L) in the cell line, H187
(Additional file 3). These results are in agreement with
previous studies in which alterations of histone modi-
fiers by rearrangements were reported [17,18], and sup-
port the important role that these genes might have in
the development and maintenance of small cell lung
cancer.Table 1 EML4-ALK co-occurring fusion genes and chimeric tra
PatID HistoID Chimeric_transcript Sp Enc Total Ty
H2228 Cell-line EML4-ALK_v3 8 (8 + 8) 13 21 Int
SND1-CFTR 6 (6 + 4) 5 11 Int
DCBLD2-STXBP5L 7 (7 + 2) 2 9 Int
H3122 Cell-line SOS1-ADCY3 16 (16 + 15) 16 32 Int
EML4-ALK_v1 22 (22 + 7) 9 31 Int
S00006 AD EML4-ALK_v2 15 (15 + 4) 5 20 Int
S00054 AD EML4-ALK_v1 24 (24 + 16) 30 54 Int
PIGF-CHMP3 13 (13 + 0) 4 17 Int
SNAP29-CELSR1 8 (8 + 2) 6 14 Int
APOBEC3F-SBF1 4 (4 + 0) 1 5
S01122 AD EML4-ALK_v1 29 (29 + 8) 12 41 Int
BMI1-ABI1 14 (14 + 4) 7 21 Int
MYO10-GPC5 12 (12 + 0) 0 12 Int
ARHGEF7-ZDHHC11 8 (8 + 2) 0 8 Int
S01124 AD EML4-ALK_v1 0 4 4 Int
TAF4-LSM14B 12 (12 + 1) 2 14 Int
S01320 AD EML4-ALK_v1 21 (21 + 7) 6 27 Int
NUP85-GPC3 12 (12 + 2) 0 12 Int
NR2C1-PTPRB 15 (15 + 4) 4 19
KRIT-MAGI2 2 (2 + 3) 3 5
Table summarizing the chimeric transcripts detected in two lung cancer cell-lines a
the EML4-ALK variant detected is indicated (v1, v2, v3). The number of spanning (S
the chimeric transcripts: intra-chromosomal (Intra), inter-chromosomal (Inter), in-fraDetection of secondary rearrangements in EML4-ALK
positive cases
Paired-end RNA-seq analysis of the EML4-ALK positive
lung cancer cell-lines H3122 and H2228 revealed that in
both cases EML4-ALK co-occurred with secondary in-
frame chimeric transcripts: SOS1-ADCY3 in the case of
H3122, and SND1-CFTR and DCBLD2-STXBP5L in the
case of H2228 (Table 1; Figure 2a). We noticed that the
genes involved in EML4-ALK and SOS1-ADCY3 were lo-
cated in the same region of chromosome 2 (Figure 2b,
upper panel). In fact, the arrangement of these two
genes in the genome suggested that SOS1-ADCY3 might
be generated by the same genomic event that had caused
the EML4-ALK fusion. In order to test this hypothesis
we first performed a break-apart FISH assay (ba-FISH)
for both SOS1 and ADCY3 genes and a fusion assay for
SOS1-ADCY3 on H3122 interphase chromosomes, to
test whether the alteration happened at the genomic
level (Additional file 4). We then performed ba-FISH for
both ALK and ADCY3 separately, on metaphase chro-
mosomes of the same cell line (Figure 2b, lower panel):
in the case of ADCY3 ba-FISH we found one aberrant
single green signal with loss of the correspondent red
signal. The same pattern was observed when performing
the assay for ALK. We therefore reasoned that if bothnscripts detected with TRUP 1.0
pe-I Type-II Domains Validated
ra IF Protein_kinase .
ra IF Snase/ABC_tran RT-PCR
ra IF CUB/LCCL/F5_F8_type_C RT-PCR
ra IF RhoGEF/Guanylate_cyc RT-PCR
ra IF Protein_kinase .
ra IF Protein_kinase FISH
ra IF Protein_kinase FISH
ra IF Snf7 RT-PCR
ra IF EGF/LamininG2/LamininEGF/HRM/GPS/7tm2 RT-PCR
Not validated
ra IF Protein_kinase FISH
ra OF . RT-PCR
er IF Myosin_head/IQ/PH RT-PCR
er IF CH/SH3/RhoGEF RT-PCR
ra IF Protein_kinase FISH
ra IF FDF RT-PCR
ra IF Protein_kinase FISH
er IF Nucleopor_Nup85 RT-PCR
Not validated
Not validated
nd five lung adenocarcinoma (AD) EML4-ALK-positive tumors. Information about
p) and encompassing (Enc) reads is given, as well as additional information of
me (IF), out-of-frame (OF).
Figure 2 Genomic complexity of EML4-ALK co-occurring fusion genes. (a) Detection by transcriptome sequencing of SOS1-ADCY3 and
SND1-CFTR in the H3122 and H2228 EML4-ALK-positive cell-lines, respectively. Schematic representation of the fusion transcripts and some of the
transcriptome sequencing reads spanning the fusion point. (b) Top: schematic representation of part of chromosome 2 illustrating the location of
ADCY3, ALK, SOS1, and EML4 as well as the relative location of the FISH probes. Bottom, from left to right: ADCY3 break-apart assay, ALK break-apart
assay, and simultaneous application of ADCY3 and ALK break-apart assays on metaphase chromosomes of H3122 cells.
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together we should see the same pattern as observed
separately (that is, one single green signal), since the twogreen signals would overlap and therefore be indistin-
guishable (Additional file 5, arrow A). On the contrary, if
the two rearrangements occurred on different alleles, we
Fernandez-Cuesta et al. Genome Biology  (2015) 16:7 Page 5 of 11should be able to distinguish two separate single green
signals, one from the assay testing ALK and one for the
assay assessing ADCY3 (Additional file 5, arrow B). The
combined ALK-ADCY3 assay only generated one single
green signal suggesting that the two rearrangements
were likely to be physically linked (Figure 2b, lower
panel). In addition to these two cell-lines, we validated
at least one secondary in-frame chimeric transcript in
four additional EML4-ALK positive primary tumors:
SNAP29-CELSR1 and PIGF-CHMP3 in sample S00054;
MYO10-GPC5 and ARHGEF7-ZDHHC11 in S01122;
TAF4-LSM14B in S01124; and NUP85-GPC3 in S01320
(Table 1).
Although fusion genes are not necessarily expected
to be accompanied by changes in gene copy number
(for instance, balanced translocations are copy neutral
alterations), for many of these samples, for which copy
number data were available, we observed well-defined
breakpoints suggesting these events happen at the gen-
omic level and not as a consequence of trans-splicing [19]
(Additional file 6). These data suggest that the recurrentFigure 3 Comparison between TRUP and other publically available fu
breakpoint assembly after a sensitive detection of potential fusion points. N
RNA-seq analysis pipelines, that is, the mapping results are shared for fusio
various split-read mapping strategy specifically for fusion detection, genera
for other purposes. (b) Computing resources consumed by TRUP and othe
step of mapping are isolated for each tool to indicate the cost only for fus
that TRUP is run with STAR as the mapper instead of GSNAP. (c) A heatma
for candidates predicted by at least two tools in sample S00054 (referred to
indicates that TRUP is run with STAR as the mapper instead of GSNAP. Undfusions in lung cancer might be reciprocal and balanced
rather than merely accompanied by broad destruction of
otherwise non-oncogenic chromosomal DNA.
Comparison of TRUP to alternative fusion detection tools
In order to evaluate the performance of TRUP we ap-
plied eight additional fusion detection tools to the data
of sample S00054: chimerascan [4], FusionHunter [20],
FusionMap [9], TopHat-Fusion [8], deFuse [7], SOAP-
fuse [21], FusionSeq [6], and BreakFusion [10]. For two
tools (FusionSeq and BreakFusion) evaluation could not
be carried out because of computational limitations. De-
tails about parameter settings are provided in Additional
file 7. Despite the fact that most tools use both read-pair
analysis and split-read mapping for the detection of fu-
sion transcripts, they vary widely in terms of resources
required and computing time (Figure 3a and b). Al-
though TRUP additionally capitalizes on regional assem-
bly of potential fusion-points, its overall performance in
terms of disc space, memory size, and running time is
superior to the others (Figure 3b). Also, even though thesion detection tools. (a) Feature comparison: TRUP adopts
ote that only TRUP and TopHat-Fusion are integrated into regular
n detection and regular RNA-seq analysis. Alternative tools adopt
ting customized mapping results, which could not be easily re-used
r tools for processing the data of sample S00054: resources used in the
ion detection and further processing (excl.: excluding). TRUP* indicates
p showing the number of non-redundant reads spanning fusion-points
as ‘shared fusions’ which is used as a gold set for evaluation). TRUP*
erlined fusions are experimentally validated.
Figure 4 Comparison of TopHat-Fusion with TRUP analysis
tools. The fusion candidates found by TRUP and TopHat-Fusion on
sample S00054, plotted by the number of non-redundant spanning
reads reported by the two tools. The horizontal and vertical dashed
lines indicate the threshold of three spanning reads for calling a
chimeric transcript. The diagonal dashed line is plotted to show that
TRUP usually reports more reads spanning a fusion point. The axes
are in log2 scale. The unique calls to each algorithm are jittered to
avoid over-plotting.
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case of TRUP, the re-usability of the mapped data will
eventually save time when regular RNA-seq analyses are
performed. Alternatively, STAR can be used, as this map-
per dramatically decreases the mapping time (Figure 3b)
although it is a little less sensitive than GSNAP (Figure 3c).
Notably, only the mapping results generated by TRUP and
TopHat-Fusion are reusable for regular RNA-seq analysis,
whereas other tools perform customized split-read map-
ping specifically for fusion detection (Figure 3a).
By using relaxed criteria requiring at least two sup-
porting reads with a minimum of one read spanning the
fusion-point, the seven tools reported from four to 542
fusion transcripts in sample S00054 (Figure 3c). Since
the full set of true-positive predictions was not available
we took the set of predictions shared across tools as gold
set. There were in total 21 fusion transcripts detected by
at least two independent tools, including three experi-
mentally validated ones. Despite the low stringency set-
tings, most alternative tools were only able to detect the
EML4-ALK fusion but not the additional two experi-
mentally validated chimeric transcripts. Three tools
showed a high number of unique predictions suggesting
a high number of false-positives. In case of FusionMap
this might be due to the fact that this tool primarily re-
lies on a single method (split-read mapping) not offering
the use of a complementary approach for eliminating
false-positives. By contrast, TRUP combines sensitive split-
read alignment and discordant read-pair analysis with
regional breakpoint assembly, thus achieving a better
balance between sensitivity and total number of predictions.
Due to the dependence on partial and chimeric align-
ments for the selection of potential breakpoints, GSNAP
becomes the first choice owing to its ability in sensitive
split-read mapping although with a relatively slow speed.
Since runtime might be a limiting factor in large-scale
projects we optionally provide the extremely fast mapper
STAR as an alternative to GSNAP. When using STAR to
process sample S00054, the performance of TRUP re-
mains high (Figure 3c) with a much-reduced running
time (Figure 3b). Sixteen out of 21 fusions in the gold
set were found by TRUP with STAR (36 fusions pre-
dicted in total), showing a slightly lower recall and com-
parable precision as compared to GSNAP (19 found, 40
predicted). Nevertheless, such a recall is still higher than
that of other fusion prediction tools.
We compared TopHat-Fusion and TRUP in more detail
since they showed the best performance (the harmonic
mean of recall and precision for TRUP is 0.62 and for
TopHat-Fusion is 0.49, highest among all the tools) with a
total of 20 and 40 predicted fusion events, respectively
(Additional files 8 and 9). For candidates with very low
coverage, disagreements between the two tools were ob-
served, indicating higher uncertainty for calling fusiontranscripts with low expression. After manually checking
the calls unique to TRUP, we only found a single candi-
date that might be considered as a false positive. This can-
didate exhibited a breakpoint located in a repetitive region
and also showed a low spanning score, which summarizes
the confidence of supporting evidence of the spanning
reads (Materials and methods). In order to avoid using
suboptimal parameter setting for TopHat-Fusion, we al-
ternatively used the default settings and adjusted the
TRUP parameters accordingly. We therefore increased the
threshold for fusion calling as follows: presence of at least
three reads spanning the fusion point and two encompass-
ing mate pairs. TopHat-Fusion now detected eight fusion
events all of which were included in the 25 candidates
found by TRUP (Figure 4). Both tools successfully recov-
ered the EML4-ALK fusion as well as one of the secondary
fusions, SNAP29-CELSR1. However, the fusion event
PIGF-CHMP3 was only reported by TRUP. TopHat-
Fusion failed to call this true positive because the num-
ber of spanning reads was limited to two. By contrast,
TRUP detected nine fusion-spanning reads. We found
that TRUP usually reports more non-redundant span-
ning reads than TopHat-Fusion, indicating a higher
sensitivity in identifying reads showing chimeric pat-
terns. Judging from the results of the analysis of sam-
ple H3122, TRUP performs well even on paired-end
data with short insert sizes (here 70 bp) where mate
pairs overlap.
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recall, precision, and computational efficiency for the
detection of fusion events from RNA-seq data com-
pared to the alternative tools tested here. Similar to
TopHat-Fusion, TRUP can be used in a standard RNA-
seq pipeline thus diminishing the impact of the sensitive
but slower spliced-mapping procedures of GSNAP. Faster
aligners, such as STAR, can also be used in TRUP if run-
ning time is the major concern.
Recurrent inactivating RASSF8 rearrangements in cancer
We next applied the method to 17 additional primary
lung adenocarcinoma specimens (Additional file 10).
Of the 17 samples analyzed, one carried an inactivating
chimeric RASSF8 transcript (Figure 5, upper panel;
Additional file 11a). The sample was negative for EGFR
or KRAS mutations and belonged to the adenocarcinoma
of a current smoker (Additional file 10). RASSF8 is one of
the four N-terminal RASSF proteins (RASSF7-10) that be-
long to the Ras-association-domain-containing family of
proteins, which also include the classical RASSF proteins
(RASSF1-6) that are known to act as tumor suppressors
and are frequently epigenetically silenced in tumors
[22]. In order to further investigate the role of RASSF8
in lung adenocarcinoma, we silenced RASSF8 expres-
sion in the lung cancer cell line, H1395, which ex-
presses wild-type RASSF8. In comparison to the EGFP
transfected cells, silencing of RASSF8 led to a significant
increase of cell proliferation of more than 60% (P <0.0001)
(Additional file 11b). RASSF8 was not completely silenced,Figure 5 Recurrent inactivating rearrangements of RASSF8 in cancer
(upper panel) and RASSF8-MARS in the KPD osteosarcoma cell-line (lowe
of the transcriptome sequencing reads spanning the fusion point.as detected by western blotting (Additional file 11c),
suggesting that low doses rather than complete loss of
the RASSF8 protein is sufficient to induce cell prolifer-
ation. Furthermore, we identified an inactivating re-
arrangement of RASSF8 in the osteosarcoma cell line,
KPD (Figure 5, lower panel; Additional file 11a). The
breakpoint of this translocation event was also detect-
able when analyzing the copy number data (Additional
file 12) suggesting that the rearrangement happened at
the genomic level.
RASSF8 has been proposed as a new tumor suppressor
in lung cancer. However, genetic data to support this
notion have so far been missing [22-24]. Our data thus
provide further support for a role of RASSF8 as a tumor
suppressor and suggest that genomic translocations might
be a relevant mechanism for the genetic inactivation of
RASSF8.Conclusions
Taken together, TRUP is a new tool for the identification
of chimeric transcripts using PE RNA-seq data, which
shows a balance between sensitivity, specificity, and
computational efficiency for prediction of fusion events.
TRUP afforded the identification of new fusion events in
the context of EML4-ALK, which were genomically linked
in one case, suggesting that in some cases EML4-ALK oc-
curs as a balanced translocation. We furthermore detected
inactivating rearrangements affecting RASSF8, supporting
its role as a tumor suppressor gene in cancer.. Identification of ASUN-RASSF8 in a lung adenocarcinoma tumor
r panel). Schematic representation of the fusion transcripts and some
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Sample preparation, DNA and RNA extraction, and
illumina sequencing
Sample preparation and DNA and RNA extraction were
performed as previously described [18]. RNAseq was per-
formed on cDNA libraries prepared from PolyA+ RNA
extracted from tumor cells using the Illumina TruSeq
protocol for mRNA. The final libraries were sequenced
with a paired-end 2 × 100 bp protocol aiming at 8.5 Gb
per sample, resulting in a 30× mean coverage of the an-
notated transcriptome. All the sequencing was carried
out on an Illumina HiSeq 2000 sequencing instrument
(Illumina).
Analysis of chromosomal gene copy number (SNP 6.0)
Hybridization of the Affymetrix SNP 6.0 arrays was
carried out according to the manufacturers’ instructions
and analyzed using a previously described method [18].
TRUP pipeline
Development of TRUP (version 1.0 to 2.0)
The differences between 1.0 and 2.0 TRUP are two-fold:
(1) the mapping tool: from TopHat to GSNAP; and (2)
whereas TRUP 1.0 feeds the total (pooled) abnormal reads
into assembly, TRUP 2.0 assembles the reads surrounding
each potential breakpoint detected from GSNAP align-
ments. In the early development stage TRUP 1.0 was
tested on cell line data. The validation of the predictions
was used to guide us to improve TRUP to 2.0. Below only
the strategy of TRUP 2.0 is described as the old version
1.0 is deprecated.
Sensitive split-read and read pair mapping against the
genome
TRUP maps PE RNA-seq reads onto the Hg19 reference
genome using GSNAP, a hash-table based spliced aligner
[11]. It breaks a read into short seeds to localize the
alignment, followed by iterative extension of candidate
regions and merging of initial seeds to the exact spliced
alignment. It has been shown that GSNAP predicts spli-
cing alignments with high sensitivity among many avail-
able RNA-seq mappers [25], partly due to its unbiased
evaluation of both un-spliced and spliced mapping of
the same read [26]. Besides the ability to map splicing
junction reads, GSNAP (version 2013-09-30 is used in
this study) can report chimeric and partial alignments of
an individual read, which are usually un-mappable by
other mappers. A read is chimeric if it spans two differ-
ent chromosomes/strands or a longer distance than the
maximum allowed intron length. Partially aligned reads
contain unmappable sequences at one of its ends that
are clipped. These reads are the source for the identifica-
tion of possible fusion junctions. In addition to GSNAP,a recent mapper, STAR, can also be used for the read
alignment in TRUP (version 2.4.0 is tested).
Relaxed detection of candidate regions containing
breakpoints
TRUP searches for chimeric and partial alignments indi-
cating reads spanning possible fusion points. The informa-
tion about discordant pairs is also incorporated. A read
pair is discordant if the two ends are mapped to two dif-
ferent chromosomes, different strands or locations with a
distance longer than the maximum allowed intron length.
Chimeric reads are split and aligned as discordant pairs. A
potential breakpoint is called from a read X with length l
if it satisfies one of the following criteria (strength of evi-
dence from high to low, tN are user defined thresholds
whose default is applied): (1) X shows chimeric mapping;
(2) X is partially aligned with a discordant mate and the
unmapped part should be at least (kmer < =1/5 l < =3/2
kmer) bp in size with no undecided nucleotides. kmer is
set in the genome database for GSNAP (16 bp or less).
Within the nearby ±200 bp region of X, TRUP requires
the existence of at least t1 (default: 2) other supporting
read alignments with discordant mates consistent with X.
(iii) For partially aligned X with a shorter unmapped seg-
ment having a discordant mate, TRUP requires at least t2
(default: 3) other discordant read alignments consistent with
X. (iv) For a group of t3 (default: 4) entirely aligned discord-
ant read pairs that are all consistent with a fusion point, the
potential breakpoint will be set to the locations where the
reads’ 3′ ends extend farthest. If STAR is used as mapper,
the chimeric junctions for each read produced by STAR
are incorporated into the breakpoint calls, in addition to
the ones identified by scanning the mapping results.
TRUP groups the breakpoint calls if they are within
200 bp in distance after removing calls from repetitive
region. The call with the strongest evidence will be used
as the group representative. A candidate region is defined
as ±250 bp centered on each breakpoint call.
De novo assembly of read pairs anchored in candidate
regions
TRUP extracts the abnormal read pairs (discordant pairs,
singletons, and reads showing partial or chimeric align-
ments) anchored in a candidate region and feeds them
into a regional assembly by using Velvet [13] and Oases
[14]. Oases is a Bruijn graph-based assembler that receives
a preliminary assembly produced by Velvet as input. Oases
is sufficiently sensitive and accurate to assemble pos-
sible alternative isoforms throughout a wide spectrum
of expression levels [14].
Filtration and prioritization of fusion candidates
The assembled junction sequences are aligned back to
the reference genome using BLAT [27]. After removing
Fernandez-Cuesta et al. Genome Biology  (2015) 16:7 Page 9 of 11the non-unique segment hits (that is, mapping to mul-
tiple regions), TRUP concatenates the remaining partial
alignments into longer ones, sometimes resulting in al-
ternative mappings of the assembled sequence. The best
and second best concatenated alignments (with aggre-
gated score q1 and q2) for each assembled sequence with
length q0 are used to calculate an alignment score (Q) as
adopted by BreakFusion [10], where Q ¼ e q1−q010 −e q2−q010 .
TRUP then queries for those candidate sequences with
their best paths exhibiting partial alignments, with min-
imal overlap (15 nt), to two different genes representing
putative fusion junctions. TRUP flags the candidates
whose fusion points are located in repetitive regions or
UCSC Self-Chain annotated regions, both of which can
indicate possible misalignments or incorrect assemblies
due to sequence similarities.
Read pairs which are improperly aligned (including
both assembly-derived and initially unmapped read
pairs) can be either a direct support for a putative fusion
junction if one end spans the fusion point with at least
13 nt aligned on both sides, or an indirect support that
encompasses the fusion point. The junctions supported
by at least two non-redundant supporting reads are re-
ported. TRUP ranks the fusion candidates based on the
following parameters applied in order: (1) the Spanning




Li þ Ri that takes into account both
the number of independent spanning reads N and the
mapping balance of each spanning read i on the left and
right side of the fusion point (with mapping distance Li
and Ri, respectively); (ii) the number of independent
encompassing read pairs; (iii) the alignment score of
junction sequence Q. An additional filtration step was
used to filter out those predictions with low (less than
5) total supporting reads (non-redundant), with low span-
ning score (less than 1) and/or those with both breakpoints
residing in self-chain region or repetitive region. Isoform
junctions for the same gene fusion were merged.
TRUP also has several other modules for RNA-seq
analysis in general, such as quality assessment, gene/
transcript expression quantification, and differential ex-
pression analysis. TRUP is available at [28].
ADCY3, SOS1, ALK, and EML4 FISH break apart assays
A dual-color break-apart fluorescence in-situ hybridization
(FISH) assay was developed to assess for ADCY3, SOS1,
ALK, and EML4 (chromosome 2) rearrangements on the
chromosomal level as described earlier [29]. All centro-
meric BAC clones were labeled red using biotin and all
telomeric BAC clones were labeled green using digoxi-
genin. In brief, for the ADCY3 break-apart assay, we used
the BAC clone CTD-3252C16 for centromeric labeling
with biotin (eventually producing a red signal) and RP11-1109B14 for telomeric labeling with digoxigenin (eventu-
ally producing a green signal). Similarly, for the SOS1
break-apart assay, we used BAC clone RP11-708G9 for
centromeric labeling and CTD-2026H4 for telomeric la-
beling, for the ALK break-apart assay RP11-993C21 was
used as the centromeric probe and RP11-984I21 was
used as the telomeric probe, and for the EML4 break-
apart assay, RP11-368 J11 was used as the centromeric
labeled probe and RP11-142 M12 was used as the telo-
meric labeled probe. Metaphase spreads were prepared
as previously described [29]. FISH on the metaphase
spreads was performed by pre-treating the slides with
2x SSC solution and digesting it with Digest-All III (di-
lution 1:2). FISH probes were added to the metaphase
spreads and co-denatured at 85°C for 4 min. and hybrid-
ized overnight at 37°C. Post-hybridization, slides were
washed with 0.5x SSC and streptavidin-Alexa-594 con-
jugates (dilution 1:200) and anti-digoxigenin-FITC (di-
lution 1:200) were added to the slides. Counterstaining
was performed using 4′,6-Diamidin-2′ phenylindoldihy-
drochlorid (DAPI) and mounted. All slides were analyzed
under a 63x oil immersion objective using a fluorescence
microscope (Zeiss, Jena, Germany) and images were cap-
tured using the Metafer 4 software (Metasystems, Altlus-
sheim, Germany). Assessment of the experiments was
done independently by two evaluators (RM and SP). Gene
rearrangements were defined as follows: a loss of a signal,
resulting in either a single red or single green signal for at
least one allele is referred to as a rearrangement through
deletion, or a wild-type allele displays a juxtaposed red
and green signal (mostly forming a yellow signal).
RASSF8 knockdown
A total of 60,000 cells per well were seeded in 2.5 mL
culture media in six well plates 1 day before the transfec-
tion. Triplicates were made. For the transfection 1.5 mL of
Opti-MEM and 15 μL of Lipofectamine RNAiMax (Life
Technologies), were mixed and incubated for 5 min at
room temperature. After 5 min 400 ng of esiRNA were in-
cubated for 20 min. Then 500 μL of the mix were added
dropwise to each well. After 6 days cells were counted.
Additionally, the triplicates were pulled, centrifuged 5 min,
4°C, 13,500 rpm, washed with PBS and resuspended with
lysis buffer (1 mL of 10x lysis buffer (Cell Signaling), one
tablet of Protease Inhibitor (Roche), 200 μL of phosphat-
ase inhibitor cocktail III (Merck), 5 μL of 200 mM PMSF
(Carl Roth), filled up to 10 mL). After 10 min incubation
on ice, samples were centrifuged 10 min, 4°C, 13,500 rpm,
and supernatants were transferred to new tubes. Protein
determination was assessed with BCA Kit (Pierce). Western
blot was performed according with standard procedures.
The antibodies used were: RASSF8 (4B1) mouse monoclo-
nal (Santa Cruz, 1:250), goat anti mouse HRP (Millipore,
1:3,000), and ß-actin HRP conjugated (Santa Cruz, 1:3,000).
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Transcriptome sequencing data and affymetrix 6.0
(copy number) data have been deposited at the European
Genome-phenome Archive under the accession code
EGAS00001000659.
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